MindImmune Therapeutics, Inc.
MindImmune Therapeutics is dedicated to developing novel therapeutics for brain diseases by targeting the immune system. Their mission is to turn insights into the nervous and immune systems into breakthrough treatments, particularly focusing on Alzheimer’s disease. They leverage deep knowledge of neuroinflammation and immune effector mechanisms to create innovative drug discovery platforms aimed at neurodegenerative and neuropsychiatric disorders.
Industries
Nr. of Employees
small (1-50)
MindImmune Therapeutics, Inc.
Patents
Benzamides-containing compounds and their use in the treatment of epilepsy
US-10238654-B2
View Details
Benzamides-containing compounds and their use in the treatment of epilepsy
US-10238654-B2
View DetailsProducts
Antibody therapeutic to block peripheral immune cell infiltration to the brain
A biologic program aimed at preventing recruitment or entry of specific peripheral innate immune cells into the brain to reduce synaptic damage associated with neurodegenerative disease, initially focused on Alzheimer’s disease.
Pipeline of immune‑targeting therapeutics for brain disease
A portfolio approach developing multiple therapeutic candidates tailored to aberrant immune activity underlying neurodegenerative and neuropsychiatric disorders.
Antibody therapeutic to block peripheral immune cell infiltration to the brain
A biologic program aimed at preventing recruitment or entry of specific peripheral innate immune cells into the brain to reduce synaptic damage associated with neurodegenerative disease, initially focused on Alzheimer’s disease.
Pipeline of immune‑targeting therapeutics for brain disease
A portfolio approach developing multiple therapeutic candidates tailored to aberrant immune activity underlying neurodegenerative and neuropsychiatric disorders.
Services
End‑to‑end preclinical program design and execution, including efficacy studies in CNS models, translational biomarker program development, CMC assay development/qualification, and preparation of studies to support IND submissions.
Research collaborations with academic institutes and industry partners to advance mechanistic studies, biomarker discovery, and early therapeutic programs.
End‑to‑end preclinical program design and execution, including efficacy studies in CNS models, translational biomarker program development, CMC assay development/qualification, and preparation of studies to support IND submissions.
Research collaborations with academic institutes and industry partners to advance mechanistic studies, biomarker discovery, and early therapeutic programs.
Expertise Areas
- Neuroimmunology research
- Therapeutic antibody development
- Preclinical and IND‑enabling development
- Translational biomarker development
Key Technologies
- Monoclonal antibody therapeutics
- Lipid nanoparticle (LNP) formulation
- CAR‑monocyte / CAR‑M cell therapy approaches
- Translational biomarker assays for immune cell recruitment
News & Updates
Dr. Mike Poole recently passed away after a long fight with cancer. The field lost an incredibly visionary, talented, and influential neurologist and researcher in the neuroscience community.
MindImmune Therapeutics appointmens Brad Margus and Robert Michael Poole, MD, FACP to its Board of Directors, with Mr. Margus assuming the role of Board Chair.
Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures, and several private investors.
Nipping Alzheimer’s disease in the blood
RightHill Ventures Commits $1.5 Million to Slater-Backed Drug Discovery Company
Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer’s disease and other diseases of the central nervous system
Dr. Mike Poole recently passed away after a long fight with cancer. The field lost an incredibly visionary, talented, and influential neurologist and researcher in the neuroscience community.
MindImmune Therapeutics appointmens Brad Margus and Robert Michael Poole, MD, FACP to its Board of Directors, with Mr. Margus assuming the role of Board Chair.
Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures, and several private investors.
Nipping Alzheimer’s disease in the blood
RightHill Ventures Commits $1.5 Million to Slater-Backed Drug Discovery Company
Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer’s disease and other diseases of the central nervous system